Abstract
Melanoma is a tumor that forms as a result of malignant transformation of melanin-producing pigment cells (melanocytes). It is the most aggressive form of skin cancer and is characterized by high resistance to chemotherapeutic drugs, which results in a need to explore alternative methods for this disease therapy. Currently, new approaches to cancer treatment are being intensely developed, oncolytic immunotherapy being one of them. This approach consists in using viruses as targeted tumor-specific cytolytic agents capable of stimulating both tumor-specific and nonspecific immune responses. A considerable body of research is currently aimed on improving the immunostimulatory properties of viruses by inserting the genes encoding immunomodulatory proteins or tumor-specific antigenic determinants into viral genomes. For melanoma, the highest number of tumor-associated antigens (TAAs) has been identified, which serve as the basis for the development of anti-tumor DNA vaccines. The immunogenicity and efficacy of these drugs, however, remain low. The bottlenecks in using DNA vaccines to treat cancer are considered to be imperfect design of polyepitope constructs, as well as inefficient delivery of therapeutic molecules directly to the target cells. A partial solution to these problems may be represented by the use of oncolytic viruses as vectors for the delivery of artificial immunogens. The recombinant vaccinia virus was obtained by transient dominant selection. The cytolytic activity of the obtained virus was tested using the MTT assay. The oncolytic activity of the virus was assessed in the mouse xenograft model obtained using malignant SK-Mel-28 cells. This paper reports the production of a recombinant L-IVP_oncoM virus, the oncolytic virus for the delivery of anticancer therapeutic genes into the cells, on the basis of the vaccinia virus strain L-IVP. Toward this end, the gene encoding the Granulocyte-macrophage colony-stimulating factor (GM-CSF) and the artificial gene encoding a polyepitope immunogen containing the epitopes of the antigens over-expressed in melanoma cells were inserted into the virus genome. These insertions were located in the proximity of the genes encoding thymidine kinase (J2R) and viral growth factor (C11L), respectively. The properties of L-IVP_oncoM were studied in in vitro experiments using cell cultures of various origin and in the in vivo experiments using the mouse xenograft model. The basic experiments to assess the biological properties of the obtained L-IVP_oncoM, which are necessary to characterize the oncolytic virus, have been carried out.
Similar content being viewed by others
REFERENCES
Cancer Facts & Figures 2017, Atlanta, GA: American Cancer Society, 2017.
Luke, J.J., Flaherty, K.T., Ribas, A., and Long, G.V., Targeted agents and immunotherapies: Optimizing outcomes in melanoma, Nat. Rev. Clin. Oncol., 2017, vol. 14, pp. 463–482.
Axelrod, M.L., Johnson, D.B., and Balko, J.M., Emerging biomarkers for cancer immunotherapy in melanoma, Semin. Cancer Biol., 2018, vol. 52, pp. 207–215.
Kaufman, H.L., Kohlhapp, F.J., and Zloza, A., Oncolytic viruses: A new class of immunotherapy drugs, Nat. Rev. Drug Discovery, 2015, vol. 14, no. 9, pp. 642–662.
Ricca, J.M., Oseledchyk, A., Walther, T., Liu, C., Mangarin, L., Merghoub, T., et al., Pre-existing immunity to oncolytic virus potentiates its immunotherapeutic efficacy, Mol. Ther., 2018, vol. 26, pp. 1008–1019.
Prestwich, R.J., Ilett, E.J., Errington, F., Diaz, R.M., Steele, L.P., Kottke, T., et al., Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication, Clin. Cancer Res., 2009, vol. 15, no. 13, pp. 4374–4381.
Kurooka, M. and Kaneda, Y., Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells, Cancer Res., 2007, vol. 1, pp. 227–236.
Chaurasiya, S., Chen, N.G., and Fong, Y., Oncolytic viruses and immunity, Curr. Opin. Immunol., 2018, vol. 51, pp. 83–90.
Burnette, W.N., “Western blotting”: Electrophoretic transfer of proteins from sodium dodecyl sulfate - polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A, Anal. Biochem., 1981, vol. 112, pp. 195–132.
Siegel, R., Ma, J., Zou, Z., and Jemal, A., Cancer statistics 2014, CA Cancer J. Clin., 2014, vol. 64, pp. 9–29.
Sergeev, Al.A., Kabanov, A.S., Bulychev, L.E., Sergeev, Ar.A., Pyankov, O.V., Bodnev, S.A., et al., The possibility of using the ICR mouse as an animal model to assess antimonkeypox drug efficacy, Transboundary Emerging Dis., 2016, vol. 63, pp. 419–430.
González-Galarza, F.F., Takeshita, L.Y., Santos, E.J., Kempson, F., Maia, M.H., et al., Allele frequency net 2015 update: New features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations, Nucleic Acids Res., 2014, vol. 43, pp. 784–788.
Duan, X., Hisaeda, H., Shen, J., Tu, L., Imai, T., Chou, B., et al., The ubiquitin–proteasome system plays essential roles in presenting an 8-mer CTL epitope expressed in APC to corresponding CD8+ T cells, Int. Immunol., 2006, vol. 18, pp. 679–687.
Seyed, N., Taheri, T., Vauchy, C., Dosset, M., Godet, Y., Eslamifar, A., et al., Immunogenicity evaluation of a rationally designed polytope construct encoding HLA-A*0201 restricted epitopes derived from Leishmania major related proteins in HLA-A2/DR1 transgenic mice: Steps toward polytope vaccine, PLoS One, 2014, vol. 9, no. 10, p. e108 848.
Falkner, F.G. and Moss, B., Transient dominant selection of recombinant vaccinia viruses, J. Virol., 1990, vol. 64, pp. 3108–3111.
Cizkova, J., Sinkorova, Z., Strnadova, K., Cervinkova, M., Horak, V., Sinkora, J., et al., The role of αβ T-cells in spontaneous regression of melanoma tumors in swine, Dev. Comp. Immunol., 2018, vol. 92, pp. 60–68.
Smith, G.L., Vanderplasschen, A., and Law, M., The formation and function of extracellular enveloped vaccinia virus, J. Gen. Virol., 2002, vol. 12, pp. 2915–2931.
Saleh, J., Murine models of melanoma, Pathol., Res. Pract., 2018, vol. 214, pp. 1235–1238.
Funding
The work was supported by the Russian Science Foundation, project no. 16-15-1010.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
COMPLIANCE WITH ETHICAL STANDARDS
Conflict of interests. The authors declare that they have no conflict of interest.
Statement on the welfare of animals. All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.
ADDITIONAL INFORMATION
Bauer T.V.—e-mail: bauer_tv@vector.nsc.ru; https://orcid.org/0000-0002-4954-9905
Tregubchak T.V.—e-mail: tregubchak_tv@vector.nsc.ru; https://orcid.org/0000-0001-9608-2044
Maksyutov A.Z.—e-mail: amaksyutov@yandex.ru; https://orcid.org/0000-0002-4027-8299
Taranov O.S.—e-mail: taranov@vector.nsc.ru; https://orcid.org/0000-0002-6746-8092
Solovieva O.I.—e-mail: solovieva@bionet.nsc.ru; https://orcid.org/0000-0002-8218-2690
Razumov I.A.—e-mail: razumov@bionet.nsc.ru; https://orcid.org/0000-0002-6756-1457
Zavjalov E.L.—e-mail: zavjalov@bionet.nsc.ru; https://orcid.org/0000-0002-9412-3874
Maksyutov R.A.—e-mail: maksyutov_ra@vector.nsc.ru; https://orcid.org/0000-0003-1314-281X
Gavrilova E.V.—e-mail: gavrilova_ev@vector.nsc.ru; https://orcid.org/0000-0002-7118-5749
Additional information
Translated by E. Martynova
About this article
Cite this article
Bauer, T.V., Tregubchak, T.V., Maksyutov, A.Z. et al. Recombinant Vaccinia Virus Promising for Melanoma Treatment. Mol. Genet. Microbiol. Virol. 35, 97–104 (2020). https://doi.org/10.3103/S0891416820020032
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.3103/S0891416820020032